Skip to content

Quick ratio at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
22.6×+1.6×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
3.6×+0.7×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
19.9×-0.4×
Scholar Rock logo
Scholar RockSRRK
8.6×-1.6×
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
1.6×+0.7×

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Calculated from Catalyst Pharmaceutical’s reported figures.

Based on the most recent quarter.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's quick ratio?
Catalyst Pharmaceutical (CPRX) reported quick ratio of 6.8× in Q1 2026.
How has Catalyst Pharmaceutical's quick ratio changed year-over-year?
Catalyst Pharmaceutical's quick ratio increased by 14.7% year-over-year, from 6× to 6.8×.
What is the long-term trend for Catalyst Pharmaceutical's quick ratio?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's quick ratio has grown at a -3.0% compound annual growth rate (CAGR), from 6.8× to 5.8×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.